These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

10631 related articles for article (PubMed ID: 11883699)

  • 21. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
    Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J
    Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.
    Bergman PJ; McKnight J; Novosad A; Charney S; Farrelly J; Craft D; Wulderk M; Jeffers Y; Sadelain M; Hohenhaus AE; Segal N; Gregor P; Engelhorn M; Riviere I; Houghton AN; Wolchok JD
    Clin Cancer Res; 2003 Apr; 9(4):1284-90. PubMed ID: 12684396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
    Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
    J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck.
    Michaluart P; Abdallah KA; Lima FD; Smith R; Moysés RA; Coelho V; Victora GD; Socorro-Silva A; Volsi EC; Zárate-Bladés CR; Ferraz AR; Barreto AK; Chammas MC; Gomes R; Gebrim E; Arakawa-Sugueno L; Fernandes KP; Lotufo PA; Cardoso MR; Kalil J; Silva CL
    Cancer Gene Ther; 2008 Oct; 15(10):676-84. PubMed ID: 18535616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma.
    Gordon LK; Ribas A; Nusinowitz S; Butterfield LH; Glaspy JA; Economou JS; Straatsma BR
    Control Clin Trials; 2004 Aug; 25(4):400-7. PubMed ID: 15296814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
    Sondak VK; Sosman JA
    Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical pharmacokinetics, manufacturing, and safety studies supporting a multicenter cancer gene therapy trial.
    Norman JA; Parker S; Lew D; Manthorpe M; Marquet M
    Hum Gene Ther; 1995 May; 6(5):549-50. PubMed ID: 7578391
    [No Abstract]   [Full Text] [Related]  

  • 28. Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma.
    Doukas J; Rolland A
    Cancer Gene Ther; 2012 Dec; 19(12):811-7. PubMed ID: 23037806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
    Hsueh EC; Morton DL
    Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
    Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
    J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients.
    Victora GD; Socorro-Silva A; Volsi EC; Abdallah K; Lima FD; Smith RB; Moyses RA; Zárate-Bladés CR; Michaluart P; Silva CL; Kalil J; Coelho V
    Cancer Gene Ther; 2009 Jul; 16(7):598-608. PubMed ID: 19197326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
    Morton DL
    Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
    Ridolfi L; Ridolfi R
    Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
    In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
    Rochlitz C; Figlin R; Squiban P; Salzberg M; Pless M; Herrmann R; Tartour E; Zhao Y; Bizouarne N; Baudin M; Acres B
    J Gene Med; 2003 Aug; 5(8):690-9. PubMed ID: 12898638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
    Kirkwood JM; Moschos S; Wang W
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2331s-2336s. PubMed ID: 16609054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination: role in metastatic melanoma.
    Pilla L; Valenti R; Marrari A; Patuzzo R; Santinami M; Parmiani G; Rivoltini L
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1305-18. PubMed ID: 16925496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
    Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 532.